欢迎收听本期的中国生物制药热点话题直播间，我是主持人Brian Yang。 今天我和Dexter Yan以及特邀嘉宾，Citeline在英国的编辑Andrew Cognahie一起，为大家带来两个话题的讨论。
第一个话题，是最近刚刚在圣地亚哥召开的AACR年会。 每年的年会，都是抗肿瘤药企争相发布最新的临床数据的机会。 这次年后上，中国公司带来哪些亮点？Dexter最近写了AACR的专题报道，我请他为大家做一个分享。 今年AACR也有很多中国公司选择在年会上发布关键临床试验结果，其中有哪些特别值得一说？例如康方生物的卡度尼利双特异性单抗的III期注册临床试验结果，中国生物制药下属企业正大天晴和益方生物合作的garsorasib（D-1553）的II期注册临床试验成果
第二个话题，是来自欧洲的分享。 Scrip在英国的Andrew McConaghie 来分享一下欧洲药企对于美国国会提出的Biosecure法案的看法，随后，最近的两个引人注目的收购交易，ProfoundBio和Genmab和Anheart Nuvation交易，其中，欧洲药企对于中国药企的创新和与中国生物初创企业做交易有哪些perspective？
最后，Andrew最近报道了勃林格的季度业绩发布会。勃林格最近也宣布，和中国生物制药集团Sino Biopharma达成三个抗肿瘤新药在中国研发的合作，BI的这个举动透露了哪些信息？
Join China-based Scrip editors Brian Yang and Dexter Yan as they look at some of the highlights from Chinese biotechs presenting clinical results at this year's annual meeting of the American Association for Cancer Research (AACR). Multiple companies including Akeso Inc. brought their latest data to the San Diego meeting, what were some of the most notable points?
UK-based Scrip senior writer Andrew McConaghie also joins the discussion to help understand two recent acquisitions involving Chinese firms, that of ProfoundBio (Suzhou) Co., Ltd. by Genmab A/S and of AnHeart Therapeutics by Nuvation Bio, Inc.
Andrew also discusses Boehringer Ingelheim GmbH's latest quarterly results and provides additional perspectives from Europe on the proposed US BIOSECURE Act.
Stories discussed in this podcast:
(Also see "AACR: Akeso’s Cadonilimab Shows 1L Potential In Adenocarcinoma" - Scrip, 9 April, 2024.)
(Also see "BIOSECURE: What’s Coming Next?" - Pink Sheet, 10 April, 2024.)
(Also see "Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company" - Scrip, 16 April, 2024.)
